Estimation of binding affinities for HEPT and nevirapine analogues with HTV-1 reverse transcriptase via Monte Carlo simulations

被引:96
作者
Rizzo, RC [1 ]
Tirado-Rives, J [1 ]
Jorgensen, WL [1 ]
机构
[1] Yale Univ, Dept Chem, New Haven, CT 06520 USA
关键词
D O I
10.1021/jm000255n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The interactions and energetics associated with the binding of 20 HEPT and 20 nevirapine nonnucleoside inhibitors of HIV-1 reverse transcriptase (RT) have been explored in an effort to establish simulation protocols and methods that can be used in the development of more effective anti-HIV drugs. Using crystallographic structures as starting points, all 40 inhibitors were modeled in the bound and unbound states via Monte Carlo (MC) statistical mechanics methods. Potentially useful descriptors of binding affinity were configurationally averaged for each inhibitor during the MC simulations, and correlations were sought with reported experimental activities. A viable regression equation was obtained using only four descriptors to correlate the 40 experimental activities with an r(2) of 0.75 and cross-validated q(2) of 0.69. The computed activities show a rmsd of 0.94 kcal/mol in comparison with experiment and an average unsigned error of 0.69 kcal/mol. The MC results reveal three physically reasonable parameters that control the binding affinities: (1) loss of hydrogen bonds with the inhibitor is unfavorable, (2) burial of hydrophobic surface area is favorable, and (3) a good geometrical fit without steric clashes is needed for the protein-inhibitor complex. It is gratifying that the corresponding descriptors are statistically the most important quantities for determining the anti-HIVRT activity for the 40 compounds. Representative examples are also given in which structural and thermodynamic information from the MC simulations is used to help understand binding differences for related compounds. A key pi -type hydrogen bond has been identified between secondary-amide nevirapine analogues and Tyr188A of HIVRT that explains their otherwise surprising activity and the ineffectiveness of nevirapine against the Y188C mutant.
引用
收藏
页码:145 / 154
页数:10
相关论文
共 67 条
[1]   NEW METHOD FOR PREDICTING BINDING-AFFINITY IN COMPUTER-AIDED DRUG DESIGN [J].
AQVIST, J ;
MEDINA, C ;
SAMUELSSON, JE .
PROTEIN ENGINEERING, 1994, 7 (03) :385-391
[2]   PRECLINICAL EVALUATION OF MKC-442, A HIGHLY POTENT AND SPECIFIC INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN-VITRO [J].
BABA, M ;
SHIGETA, S ;
YUASA, S ;
TAKASHIMA, H ;
SEKIYA, K ;
UBASAWA, M ;
TANAKA, H ;
MIYASAKA, T ;
WALKER, RT ;
DECLERCQ, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :688-692
[3]   HUMAN-IMMUNODEFICIENCY-VIRUS-1 (HIV-1)-SPECIFIC REVERSE-TRANSCRIPTASE (RT) INHIBITORS MAY SUPPRESS THE REPLICATION OF SPECIFIC DRUG-RESISTANT (E138K)RT HIV-1 MUTANTS OR SELECT FOR HIGHLY RESISTANT (Y181C-]C181I)RT HIV-1 MUTANTS [J].
BALZARINI, J ;
KARLSSON, A ;
SARDANA, VV ;
EMINI, EA ;
CAMARASA, MJ ;
DECLERCQ, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) :6599-6603
[4]  
Bohm HJ, 1996, ANGEW CHEM INT EDIT, V35, P2589
[5]   RESISTANCE TO 1-[(2-HYDROXYETHOXY)METHYL]-6-(PHENYLTHIO)THYMINE DERIVATIVES IS GENERATED BY MUTATIONS AT MULTIPLE SITES IN THE HIV-1 REVERSE-TRANSCRIPTASE [J].
BUCKHEIT, RW ;
FLIAKASBOLTZ, V ;
YEAGYBARGO, S ;
WEISLOW, O ;
MAYERS, DL ;
BOYER, PL ;
HUGHES, SH ;
PAN, BC ;
CHU, SH ;
BADER, JP .
VIROLOGY, 1995, 210 (01) :186-193
[6]   AN EXTENDED LINEAR-RESPONSE METHOD FOR DETERMINING FREE-ENERGIES OF HYDRATION [J].
CARLSON, HA ;
JORGENSEN, WL .
JOURNAL OF PHYSICAL CHEMISTRY, 1995, 99 (26) :10667-10673
[7]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[8]   AIDS therapies - The daunting challenge of keeping HIV suppressed [J].
Cohen, J .
SCIENCE, 1997, 277 (5322) :32-33
[9]   Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant [J].
Das, K ;
Ding, JP ;
Hsiou, Y ;
Clark, AD ;
Moereels, H ;
Koymans, L ;
Andries, K ;
Pauwels, R ;
Janssen, PAJ ;
Boyer, PL ;
Clark, P ;
Smith, RH ;
Smith, MBK ;
Michejda, CJ ;
Hughes, SH ;
Arnold, E .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 264 (05) :1085-1100
[10]   HIV RESISTANCE TO REVERSE-TRANSCRIPTASE INHIBITORS [J].
DECLERCQ, E .
BIOCHEMICAL PHARMACOLOGY, 1994, 47 (02) :155-169